VAR Resources Corp. Announces Update to NEX Reactivation Transaction and Name Change
VAR RESOURCES CORP.
Trading symbol: TSX-V – VAR
VAR Resources Corp. Announces Update to NEX Reactivation Transaction and Name Change
Vancouver, British Columbia – January 29, 2021 – VAR Resources Corp. (formerly Canadian International
Pharma Corp.) (the “Company”) announces that, further to its news release of November 4, 2020, it is has
received conditional approval of its application to graduate from the NEX board of the TSX Venture
Exchange (the “Exchange”) to the Exchange as a Tier 2 Mining Issuer in connection with acquisition of an
undivided 100% interest in the Hook Bay Property (the “ Property”) located in British Columbia from
Longford Capital Corp. (“Longford”) pursuant to the terms of a mineral option agreement dated October
30, 2020 (the “ NEX Reactivation Transaction ”). For more information on the Property, see the
Company’s news release of November 4, 2020. The Company closed the NEX Reactivation Transaction on
January 29, 2021 and paid $50,000 on January 28, 2021 and issued 2,200,000 comon shares (each, a
“Share”) on January 29, 2021 to Longford. The Shares issued to Longford are subject to a statutory hold
period expiring four months and one day after closing of the NEX Reactivation Transaction.
Further to its news release of December 2, 2020, th e Company has satisfed the escrow release condition
for the Subscription Receipts and accordingly, each subscription receipt has been converted, for no
additional consideration, into one unit consisting of one Share of the Company and one transferable share
purchase warrant (each, a “ Warrant”). Each Warrant shall entitle the holder thereof to acquire one Share
(each, a “ Warrant Share”) for a period of five years from the date of issuance thereof at a price of $0.14
per Warrant Share. The proceeds of the Financing are expected to be used for general working capital and
for the expenditures under the Option Agreement.
In connection with the NEX Reactivation Transactio n, the Company changed its name from Canadian
International Pharma Corp. to VAR Resources Corp. effective January 29, 2021. The common shares of
the Company will resume trading at the market open on Tuesday, February 2, 2021.
As announced in June 2015, the Company decided to pursue new business opport unities in the area of
pharmaceutcal and nutraceutical manufacturing an d distribution. The Company did not make any
material progress in any of the business opportunit ies that it pursued. A summary of the business
opportunities and the results are set out below:
On September 28, 2015, the Company entered in an exclusive distribution agreement with
Everhealth Natural Vitamin Company to distribute Everhealth’s vitamin products to the Dubai
market for a one year term. The Company did not achieve any sales and the agreement was not
renewed.
On February 10, 2016, the Company entered into a letter of intent with Nikma Darou Chimie, an
Iranian company, related to proposed licensing agreement for generic medications. In connection
with its PharmaCert Certification Program, the Company tested some of these medications and
the samples did not meet quality criteria and th e proposal did not move ahead and no shares
were issued under that proposal.
On April 25, 2016, the Company announced that it has launched the PharmaCert Certification
Program, a medication certification program using globally respected Canadian and US
standards that measure the identity, strength, quality and purity of medications based on trusted
standards, such as United States Pharmacopeia and British Pharmacopeia. On December 20,
2016, the Company received an initial order from Nano Hayat Darou Company to test a sample
under its PharmaCert Program. The samples did not meet quality criteria and the proposal did
not move ahead.
On November 16, 2016, the Company entered into a Business Development Agreement with
Bahrain Capital Group for development of the Arab Gulf Region for a one year term. The
Company did not achieve any sales and the agreement was not renewed.
In November 2017, the Company announced that it had entered into an agency agreement with a
Canadian based pharmaceutical company that discovers, develops, manufactures and markets a
broad range of healthcare products, to sell and ma rket a number of generic and over the counter
medications in Canada. The Company presented the products to a number of chain and
independent pharmacies located in British Columbia, Alberta and Saskatchewan but did not
obtain any product placements and listings for such products.
As a result of the lack of success with respect to the business opportunities in the area of pharmaceutcal
and nutraceutical manufacturing and distribution and in connection with the NEX Reactivation
Transaction, the Company will continue to focus it s business on the exploration and development of the
Property and the acquistion of other mineral resource properties.
For further information, contact Ron Schmitz at 604.685.7450.
CANADIAN INTERNATIONAL PHARMA CORP.
“Ron Schmitz”
Ron Schmitz, Director
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.